Clinical Trial Update: ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ZD1839 (Iressa) in combination with docetaxel as first-line therapy for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED